FY2025 EPS Estimates for Hologic Decreased by Zacks Research

Hologic, Inc. (NASDAQ:HOLX) – Equities researchers at Zacks Research lowered their FY2025 earnings per share estimates for Hologic in a research report issued on Wednesday, March 19th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $4.25 per share for the year, down from their previous forecast of $4.26. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.14 EPS and FY2026 earnings at $4.59 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

HOLX has been the topic of several other research reports. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Stephens restated an “overweight” rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Finally, William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

Hologic stock opened at $61.47 on Friday. The stock has a fifty day moving average price of $66.06 and a two-hundred day moving average price of $73.99. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic has a 52-week low of $60.34 and a 52-week high of $84.67.

Hedge Funds Weigh In On Hologic

Several hedge funds have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. lifted its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Brooklyn Investment Group boosted its stake in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares during the period. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the period. Trivant Custom Portfolio Group LLC raised its holdings in Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after acquiring an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its holdings in shares of Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock worth $66,000 after buying an additional 183 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.